Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study

By sjmartinez • September 11, 2024

Chalmers JD, Shteinberg M, Mall MA, O'Donnell AE, Watz H, Gupta A, Frahm E, Eleftheraki A, Rauch J, Chotirmall SH, Armstrong AW, Eickholz P, Hasegawa N, Sauter W, McShane PJ. Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-blind, placebo-controlled, dose-finding study. Eur Respir J. 2024 Sep 10:2401551. doi: 10.1183/13993003.01551-2024. Epub ahead of print. PMID: 39255990.

Tags: Dermatology, Publications

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

Augustin M, Feldman SR, Warren RB, Armstrong A, Vender R, López-Ferrer A, Dawe WH, Lambert J, Szilagyi B, Hoepken B, Warham R, Gottlieb AB. Three-Year[...]

The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial

Silverberg JI, Eichenfield LF, Armstrong AW, Bagel J, Lockshin B, Boh E, Koo J, Farberg AS, Goldberg MS, Quick AP, Lebwohl MG. The 487-gene expression[...]

Facial Swelling in a Young Adult With Type 1 Diabetes: Morbihan Disease as a Scleroderma Mimic

Shammas R, Gudino-Rosales S, Kneiber D, Sarantopoulos GP, Aung T. Facial Swelling in a Young Adult With Type 1 Diabetes: Morbihan Disease as a Scleroderma[...]